Evidence map›Paper›PMID 42149191›Full record

ReviewRecent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer2026

Molecular Ultrasound Imaging.

Anne Rix, Jasmin Baier, Fabian Kiessling

Abstract readReview
PubMed Publisher
In one paragraph

Review in Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Anne RixInstitute for Experimental Molecular Imaging, University Hospital, RWTH Aachen University, Northrhein-Westphalia, Germany.
Jasmin BaierInstitute for Experimental Molecular Imaging, University Hospital, RWTH Aachen University, Northrhein-Westphalia, Germany.
Fabian KiesslingInstitute for Experimental Molecular Imaging, University Hospital, RWTH Aachen University, Northrhein-Westphalia, Germany. fkiessling@ukaachen.de.ORCID https://orcid.org/0000-0002-7341-0399

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contrast-enhanced ultrasound (CEUS) imaging is a valuable tool for preclinical and clinical diagnostics. The most frequently used ultrasound contrast agents are microbubbles. Besides them, novel nano-sized materials are under investigation, which are briefly discussed in this chapter. For molecular CEUS, the ultrasound contrast agents are modified to actively target disease-associated molecular markers with a site-specific ligand. The most common markers for tumor imaging are related to neoangiogenesis, like the vascular endothelial growth factor receptor-2 (VEGFR2) and α

Indexed as

Contrast MediaMolecular ImagingNeoplasmsAnimalsHumansMicrobubblesNeovascularization, PathologicUltrasonographyVascular Endothelial Growth Factor Receptor-2Contrast MediaVascular Endothelial Growth Factor Receptor-2Active targetingBR55CEUSImagingIntegrinmicrobubbleUltrasound imagingVEGFR2

Identifiers

PMID42149191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.